Overview

  • Product name
    Anti-VLDL Receptor / VLDL-R antibody
    See all VLDL Receptor / VLDL-R primary antibodies
  • Description
    Rabbit polyclonal to VLDL Receptor / VLDL-R
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WB, IHC-P, Flow Cytmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide within Human VLDL Receptor/ VLDL-R aa 555-605 conjugated to keyhole limpet haemocyanin. The exact sequence is proprietary.
    Sequence:

    LREPAS IAVDPLSGFV YWSDWGEPAK IEKAGMNGFD RRPLVTADIQ WPNGI


    Database link: P98155

  • Positive control
    • Rat heart and kidney lysates; mouse embryo tissue.
  • General notes

    Previously labelled as VLDL Receptor. 

Applications

Our Abpromise guarantee covers the use of ab203271 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/100 - 1/1000. Predicted molecular weight: 96 kDa.
IHC-P 1/100 - 1/500.

When using a fluorescent probe the recommended dilution is 1/50 – 1/200.

Flow Cyt 1/20 - 1/100.

ab171870 - Rabbit polyclonal IgG, is suitable for use as an isotype control with this antibody.

 

Target

  • Function
    Binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Binding to Reelin induces tyrosine phosphorylation of Dab1 and modulation of Tau phosphorylation.
  • Tissue specificity
    Abundant in heart and skeletal muscle; also ovary and kidney; not in liver.
  • Involvement in disease
    Defects in VLDLR are the cause of cerebellar ataxia mental retardation and dysequilibrium syndrome type 1 (CMARQ1) [MIM:224050]; also known as dysequilibrium syndrome (DES) or non-progressive cerebellar disorder with mental retardation. CMARQ1 is a congenital, non-progressive cerebellar ataxia associated with disturbed equilibrium, delayed ambulation, mental retardation and cerebellar hypoplasia. Additional features include short stature, strabismus, pes planus and, rarely, seizures.
  • Sequence similarities
    Contains 3 EGF-like domains.
    Contains 8 LDL-receptor class A domains.
    Contains 6 LDL-receptor class B repeats.
  • Post-translational
    modifications
    Ubiquitinated at Lys-839 by MYLIP leading to degradation.
  • Cellular localization
    Membrane. Membrane > clathrin-coated pit.
  • Information by UniProt
  • Database links
  • Alternative names
    • FLJ35024 antibody
    • Very low density lipoprotein receptor antibody
    • Very low-density lipoprotein receptor antibody
    • VLDL R antibody
    • VLDL receptor antibody
    • VLDL-R antibody
    • VLDLR antibody
    • VLDLR_HUMAN antibody
    • VLDLRCH antibody
    see all

Images

  • All lanes : Anti-VLDL Receptor / VLDL-R antibody (ab203271) at 1/200 dilution

    Lane 1 : Rat heart lysate
    Lane 2 : Rat kidney lysate

    Secondary
    All lanes : Goat Anti-Rabbit IgG Antibody (H+L), HRP at 1/3000 dilution

    Developed using the ECL technique.

    Predicted band size: 96 kDa

  • Immunohistochemical analysis of formalin-fixed, paraffin-embedded mouse embryo tissue labeling VLDL Receptor / VLDL-R with ab203271 at 1/200 dilution, followed by conjugation to the secondary antibody and DAB staining.

References

ab203271 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab203271.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up